Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)

Capstone Therapeutics Corp. (OTCMKTS:CAPS) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013. Capstone Therapeutics Corp. (OTCMKTS:CAPS) stock performance was 4.00% in last session and finished the day at $0.260. Traded volume was 57,580.00million … Continue reading Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)

Biotech New Highs: Sinovac Biotech (NASDAQ:SVA), Neuralstem (NYSEMKT:CUR), Durata Therapeutics Inc (NASDAQ:DRTX), Recro Pharma (NASDAQ:REPH)

Sinovac Biotech Ltd (NASDAQ:SVA) a leading biopharmaceutical company in China has reported its fourth quarter and full year unaudited results for the period ending December 31, 2013. Sinovac Biotech Ltd. (NASDAQ:SVA) stock performance was 17.13% in last session and finished the day at $8.07. Traded volume was 4,876,818 million shares in the last session and the average volume of the stock remained 342.45 million shares. … Continue reading Biotech New Highs: Sinovac Biotech (NASDAQ:SVA), Neuralstem (NYSEMKT:CUR), Durata Therapeutics Inc (NASDAQ:DRTX), Recro Pharma (NASDAQ:REPH)

Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) announced that its phase 3 MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients didn’t meet its first or second coprimary endpoint. Agenus Inc (NASDAQ:AGEN) stock performance … Continue reading Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 2.14% in last session and finished the day at $27.16. Traded volume was 61,391.00 shares in the last session and the average volume of the stock remained 27,510.00 shares. The beta of the stock remained 0.90. BioSpecifics Technologies Corp. … Continue reading Biotech New Highs: BioSpecifics Technologies (NASDAQ:BSTC), Five Prime Therapeutics (NASDAQ:FPRX), IGI Laboratories (NYSEMKT:IG), Durata Therapeutics (NASDAQ:DRTX)

Arch Coal Inc., (NYSE:ACI) a producer of the commodity in Appalachia and the western United States, rose the most in more than two months after reporting an increase in cash on hand and profit that beat analysts’ estimates. The company also said it had $1.05 billion of cash and short-term investments as of Sept. 30, almost $60 million more than at the end of the … Continue reading Eye Catching Stocks: Arch Coal Inc. (NYSE:ACI), Zynga Inc (NASDAQ:ZNGA), Microvision Inc. (NASDAQ:MVIS), Durata Therapeutics, Inc. (NASDAQ:DRTX), Territorial Bancorp Inc. (NASDAQ:TBNK)

Repligen Corp. (NASDAQ:RGEN) released its earnings data on Monday, 11 Aug 2014. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.06 by $0.03. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s … Continue reading Stock Runners: Repligen (NASDAQ:RGEN), Durata Therapeutics (NASDAQ:DRTX), Acadia Realty Trust (NYSE:AKR), International Game Technology (NYSE:IGT), DDR Corp. (NYSE:DDR)